CLINICAL TRIALS PROFILE FOR HQP1351

Clinical Trials for HQP1351

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03594422 ↗	A Study of HQP1351 in Patients With GIST or Other Solid Tumors	Recruiting	HealthQuest Pharma Inc.	Phase 1	This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
NCT03594422 ↗	A Study of HQP1351 in Patients With GIST or Other Solid Tumors	Recruiting	Ascentage Pharma Group Inc.	Phase 1	This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
NCT03882281 ↗	Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia	Completed	HealthQuest Pharma Inc.	Phase 1	The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately（Selection of high-fat meal spectrum：《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
NCT03882281 ↗	Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia	Completed	Ascentage Pharma Group Inc.	Phase 1	The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately（Selection of high-fat meal spectrum：《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
NCT03883087 ↗	A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation	Active, not recruiting	Ascentage Pharma Group Inc.	Phase 2	The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) harboring T315I mutation. The efficacy of HQP1351 was determined by evaluating the subjects' major cytogenetic response (MCyR).
NCT03883100 ↗	A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation	Active, not recruiting	Ascentage Pharma Group Inc.	Phase 2	The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in accelerated phase (CML-AP) harboring T315I mutation. The efficacy of HQP1351 was determined by evaluating the subjects' major hematologic response (MaHR).

Clinical Trial Conditions for HQP1351

Condition Name

Condition Name
Intervention	Trials
Chronic Myeloid Leukemia, Chronic Phase	4
Chronic Myeloid Leukemia	1
Third Generation TKI	1
Chronic Myeloid Leukemia - Accelerated Phase	1

Condition MeSH

Condition MeSH
Intervention	Trials
Leukemia, Myeloid	7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	7
Leukemia	6
Leukemia, Lymphoid	1

Clinical Trial Locations for HQP1351

Trials by Country

Trials by Country
Location	Trials
China	39
United States	7

Trials by US State

Trials by US State
Location	Trials
Texas	1
Ohio	1
Georgia	1
California	1
Arkansas	1

Clinical Trial Progress for HQP1351

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	4
Phase 1	4

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	3
Active, not recruiting	3
Completed	2

Clinical Trial Sponsors for HQP1351

Sponsor Name

Sponsor Name
Sponsor	Trials
Ascentage Pharma Group Inc.	7
HealthQuest Pharma Inc.	4
Shenzhen Second People's Hospital	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	11
Other	6